Reviva Pharmaceuticals Holdings Stock Performance
| RVPH Stock | USD 1.80 0.07 3.74% |
Reviva Pharmaceuticals holds a performance score of 9 on a scale of zero to a hundred. The company holds a Beta of 2.79, which implies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Reviva Pharmaceuticals will likely underperform. Use Reviva Pharmaceuticals semi variance, as well as the relationship between the daily balance of power and price action indicator , to analyze future returns on Reviva Pharmaceuticals.
Risk-Adjusted Performance
OK
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Reviva Pharmaceuticals Holdings are ranked lower than 9 (%) of all global equities and portfolios over the last 90 days. Despite fairly weak basic indicators, Reviva Pharmaceuticals demonstrated solid returns over the last few months and may actually be approaching a breakup point. ...more
1 | RVPH Year-End OLE Update | 11/19/2024 |
2 | Acquisition by Margolin Richard A of 8200 shares of Reviva Pharmaceuticals at 2.52 subject to Rule 16b-3 | 12/10/2024 |
3 | Reviva Pharmaceuticals Upcoming Events May Generate Excitement, But Cash Is Low - Seeking Alpha | 12/11/2024 |
4 | Reviva Announces Positive Preliminary Topline Data for the Long-Term Open Label Extension Portion of the Phase 3 RECOVER Study Evaluating Brilaroxazine in Schiz... | 12/16/2024 |
5 | Reviva Pharmaceuticals Strengthens Financial Position with Offering - Yahoo Finance | 12/19/2024 |
6 | Reviva to Participate in the Lytham Partners 2025 Investor Healthcare Summit | 01/07/2025 |
7 | Reviva Pharmaceuticals Unusual Options Activity | 01/21/2025 |
8 | Reviva to Participate in the 2025 BIO CEO Investor Conference | 01/30/2025 |
9 | Acquisition by Vedanta Partners, Llc of 869565 shares of Reviva Pharmaceuticals at 2.4 subject to Rule 16b-3 | 02/07/2025 |
| Begin Period Cash Flow | 18.5 M |
Reviva |
Reviva Pharmaceuticals Relative Risk vs. Return Landscape
If you would invest 122.00 in Reviva Pharmaceuticals Holdings on November 20, 2024 and sell it today you would earn a total of 58.00 from holding Reviva Pharmaceuticals Holdings or generate 47.54% return on investment over 90 days. Reviva Pharmaceuticals Holdings is currently generating 1.1498% in daily expected returns and assumes 9.6484% risk (volatility on return distribution) over the 90 days horizon. In different words, 85% of stocks are less volatile than Reviva, and 78% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Reviva Pharmaceuticals Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Reviva Pharmaceuticals' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Reviva Pharmaceuticals Holdings, and traders can use it to determine the average amount a Reviva Pharmaceuticals' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.1192
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | RVPH | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 9.65 actual daily | 86 86% of assets are less volatile |
Expected Return
| 1.15 actual daily | 22 78% of assets have higher returns |
Risk-Adjusted Return
| 0.12 actual daily | 9 91% of assets perform better |
Based on monthly moving average Reviva Pharmaceuticals is performing at about 9% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Reviva Pharmaceuticals by adding it to a well-diversified portfolio.
Reviva Pharmaceuticals Fundamentals Growth
Reviva Stock prices reflect investors' perceptions of the future prospects and financial health of Reviva Pharmaceuticals, and Reviva Pharmaceuticals fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Reviva Stock performance.
| Return On Equity | -17.95 | ||||
| Return On Asset | -3.28 | ||||
| Current Valuation | 78.37 M | ||||
| Shares Outstanding | 46.58 M | ||||
| Price To Book | 8.35 X | ||||
| EBITDA | (39.5 T) | ||||
| Net Income | (39.26 M) | ||||
| Cash And Equivalents | 23.19 M | ||||
| Cash Per Share | 1.13 X | ||||
| Total Debt | 17.98 M | ||||
| Current Ratio | 6.72 X | ||||
| Book Value Per Share | (0.30) X | ||||
| Cash Flow From Operations | (28.32 M) | ||||
| Earnings Per Share | (1.08) X | ||||
| Market Capitalization | 83.84 M | ||||
| Total Asset | 23.7 M | ||||
| Retained Earnings | (134.35 M) | ||||
| Working Capital | 6.53 M | ||||
About Reviva Pharmaceuticals Performance
By evaluating Reviva Pharmaceuticals' fundamental ratios, stakeholders can gain valuable insights into Reviva Pharmaceuticals' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Reviva Pharmaceuticals has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Reviva Pharmaceuticals has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | -1.9 M | -1.8 M | |
| Return On Capital Employed | -7 M | -6.6 M | |
| Return On Assets | -1.9 M | -1.8 M | |
| Return On Equity | -7.9 M | -7.5 M |
Things to note about Reviva Pharmaceuticals performance evaluation
Checking the ongoing alerts about Reviva Pharmaceuticals for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Reviva Pharmaceuticals help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Reviva Pharmaceuticals is way too risky over 90 days horizon | |
| Reviva Pharmaceuticals may become a speculative penny stock | |
| Reviva Pharmaceuticals appears to be risky and price may revert if volatility continues | |
| Net Loss for the year was (39.26 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Reviva Pharmaceuticals Holdings currently holds about 23.19 M in cash with (28.32 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.13. | |
| Reviva Pharmaceuticals has a poor financial position based on the latest SEC disclosures | |
| Roughly 14.0% of the company outstanding shares are owned by corporate insiders | |
| Latest headline from gurufocus.com: Reviva to Participate in the 2025 BIO CEO Investor Conference |
- Analyzing Reviva Pharmaceuticals' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Reviva Pharmaceuticals' stock is overvalued or undervalued compared to its peers.
- Examining Reviva Pharmaceuticals' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Reviva Pharmaceuticals' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Reviva Pharmaceuticals' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Reviva Pharmaceuticals' stock. These opinions can provide insight into Reviva Pharmaceuticals' potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Reviva Stock analysis
When running Reviva Pharmaceuticals' price analysis, check to measure Reviva Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Reviva Pharmaceuticals is operating at the current time. Most of Reviva Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Reviva Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Reviva Pharmaceuticals' price. Additionally, you may evaluate how the addition of Reviva Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device |